New Guidance on Forced Degradation Studies for Medicines in Brazil

The stability of medicines is one of the fundamental pillars to ensure their efficacy, safety, and quality throughout their shelf life. In this context, forced degradation studies are essential tools for drug development and stability assessment. Recently, Anvisa published new guidance establishing clear directives for conducting these studies in Brazil, providing greater consistency and transparency for the pharmaceutical industry.
How China’s NMPA Review Application for Chemical Drug Changes

On February 10, 2021, The CDE (Center for Drug Evaluation) of the NMPA in China has recently released “Guidelines for Acceptance and Review of Chemical Drug Changes”GRP Blog outlines how the NMPA reviews the application after receiving it and any necessary notes when preparing the application.
China’s CDE releases Guidelines for Acceptance and Review of Chemical Drug Changes

On February 10, 2021, The CDE (Center for Drug Evaluation) of the NMPA in China has recently released “Guidelines for Acceptance and Review of Chemical Drug Changes” with Information on requirements for completing a Chemical Drug Change.
Japan’s PMDA Remote Inspections

The PMDA clarifies its requirements for conducting remote compliance inspections related to drugs and regenerative medical products.
Accelerated Approval of Detection Reagents of Coronavirus in China

The Emergency Approval of Novel Coronavirus Nucleic Acid Detection Reagent has shown the NMPA accelerated approval of seven NAD Reagents in only four days before going to the market.